← Back to Clinical Trials
Recruiting NCT06941155

NCT06941155 Gamified Combined Cognitive Bias Modification in Adults Diagnosed With OCD: Randomized Controlled Trial

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06941155
Status Recruiting
Phase
Sponsor Dokuz Eylul University
Condition Obsessive Compulsive Disorder (OCD)
Study Type INTERVENTIONAL
Enrollment 90 participants
Start Date 2025-05-14
Primary Completion 2027-04-02

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Gamified-Combined Cognitive Bias ModificationStandard Combined Cognitive Bias ModificationPlacebo

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 90 participants in total. It began in 2025-05-14 with a primary completion date of 2027-04-02.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This randomized controlled trial examines the effects of a mobile-based gamified combined cognitive bias modification (CBM-C) intervention on obsessive-compulsive symptoms, obsessive beliefs, attentional and interpretation biases, depressive symptoms, and psychological distress. The gamified CBM-C condition is compared to a standard mobile-based CBM-C and a placebo control condition. All interventions are delivered via a mobile application. Assessments are conducted at baseline, post-intervention (week 4), and 3-month follow-up.

Eligibility Criteria

Inclusion Criteria: * Age 18 years or older * Primary diagnosis of obsessive-compulsive disorder (OCD), confirmed by a licensed clinician using the Structured Clinical Interview for DSM-5 (SCID-5) * No current suicidal ideation or psychotic symptoms * Access to the internet and a mobile phone * Stable psychiatric medication use for at least one month prior to enrollment, with no changes in dosage during the 4-week intervention period * No current neurological or medical condition that would interfere with participation * Ability to perceive colored visual stimuli (e.g., no color blindness) * Not currently enrolled in another intervention-based study * Not receiving any other form of psychological treatment at the time of participation Exclusion Criteria: * Presence of active suicidal ideation or psychotic symptoms * Unstable psychiatric medication use (e.g., recent dose change within the past month or expected change during the intervention period) * Significant neurological or medical illness that may interfere with participation * Visual impairments that would prevent accurate perception of colored stimuli (e.g., color blindness) * Current participation in another clinical trial involving psychological intervention * Receiving concurrent psychotherapy or other psychological treatments outside of the study

Contact & Investigator

Central Contact

Sıla Derin, PhD

✉ siladerin@gmail.com

📞 +905543366293

Principal Investigator

Sıla Derin, PhD

PRINCIPAL INVESTIGATOR

Dokuz Eylul University, İzmir, Turkey

Frequently Asked Questions

Who can join the NCT06941155 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Obsessive Compulsive Disorder (OCD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06941155 currently recruiting?

Yes, NCT06941155 is actively recruiting participants. Contact the research team at siladerin@gmail.com for enrollment information.

Where is the NCT06941155 trial being conducted?

This trial is being conducted at Izmir, Turkey (Türkiye).

Who is sponsoring the NCT06941155 clinical trial?

NCT06941155 is sponsored by Dokuz Eylul University. The principal investigator is Sıla Derin, PhD at Dokuz Eylul University, İzmir, Turkey. The trial plans to enroll 90 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology